Oncology for the Inquisitive Mind

ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will ad…

Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel,…

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many ot…

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically …

Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers…

The second of our two GU ASCO 2024 episodes focusses on prostate and penile cancer, two diseases at different ends of the therapeutic spectrum. Prostate cancer is one of the most common cancers in me…

Genitourinary Cancers dominated ASCO24 this year, and Josh and Michael's ASCO Odyssey needed two episodes to fit it all in. Join them as they board the Nautilus with Captain Nemo in search of the bes…

Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examin…

Today, Michael and Josh approach a singular destiny to present their take on Metastatic Breast Cancer at ASCO 2024. Long has Breast Cancer been one of the most diagnosed cancers globally; these days,…

Day 3 of Oncology for the Inquisitive Mind's ASCO Odyssey and our hosts show no sign of flagging under this immense pressure, although Josh has started to give up on his famous segues. In this episod…

As the sun rises on another day at ASCO, Michael and Josh are ready to hit the ground running to bring you the latest and greatest in all things oncology in Chicago has to offer. No greek mythology t…

"Tell me, Muse, the story of that resourceful man who was driven to wander far and wide after he had sacked Troy. He saw the cities of many people and he learnt their ways. Tell us this story, goddes…

With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric…

Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease …

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian…

In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes …

As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the…

For 100 episodes, Josh and Michael have brought to your ears the latest and greatest in oncology research and treatment. In this episode, we will take a trip down memory lane, speaking about our jour…

In this episode, Josh and Michael examine the rapidly developing world of early lung cancer treatment. An area that will hopefully only grow in importance, treatment for early NSCLC is becoming ever …

On this very special episode, Josh and Michael welcome Dr Adam Brufsky, a trailblazer in the world of breast cancer treatment and a titan in the frenetic development of breast cancer therapies since …